Chemotherapy of advanced head and neck squamous carcinoma with cisplatin, fluorouracil and bleomycin administered in an outpatient schedule

A. Veronesi, M. D. Magri, S. Foladore, E. Bidoli, R. Innocente, G. Caruso, L. Barzan, R. Comoretto, S. Monfardini

Research output: Contribution to journalArticle

Abstract

From May 1983 to September 1984, 48 consecutive patients with locally advanced, recurrent and/or metastatic head and neck squamous carcinoma were treated with cisplatin 60 mg/m2 i.v. on day 1, fluorouracil 10 mg/kg i.v. push from day 1 to day 4 and bleomycin 10 mg/m2 i.v. from day 1 to day 4, every 3 weeks. In the 44 evaluable patients complete remission was observed in 4, partial remission in 9, stable disease in 19, and progression in 12, for a 29.5% response rate. When the analysis was limited to the 21 patients with PS > 70 and no previous chemotherapy or radiotherapy, the response rate was 48%. Toxicity was acceptable, and no treatment related deaths occurred. Overall median survival (all eligible patients) was 7 months. Although further studies with this combination in poor risk patients (previously treated or with PS <70) do not appear to be indicated, a more accurate assessment in good risk patients might be warranted.

Original languageEnglish
Pages (from-to)559-562
Number of pages4
JournalTumori
Volume74
Issue number5
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Chemotherapy of advanced head and neck squamous carcinoma with cisplatin, fluorouracil and bleomycin administered in an outpatient schedule'. Together they form a unique fingerprint.

  • Cite this

    Veronesi, A., Magri, M. D., Foladore, S., Bidoli, E., Innocente, R., Caruso, G., Barzan, L., Comoretto, R., & Monfardini, S. (1988). Chemotherapy of advanced head and neck squamous carcinoma with cisplatin, fluorouracil and bleomycin administered in an outpatient schedule. Tumori, 74(5), 559-562.